You are here

OxyContin maker stops promoting opioids, cuts sales staff

Purdue faces lawsuits accusing it of downplaying the painkiller's addiction risk and of misleading marketing

BT_20180212_NVPURDUE12_3305422.jpg
At least 14 states have sued Purdue for overstating the benefits of opioids for treating chronic, rather than short-term, pain. Purdue has denied the allegations in the various lawsuits.

Toronto

OXYCONTIN maker Purdue Pharma LP said on Saturday that it has cut its sales force in half and will stop promoting opioids to physicians, following widespread criticism of the ways that drugmakers market addictive painkillers.

The drugmaker said it will inform doctors on

sentifi.com

Market voices on:

Powered by GET.comGetCom